MDGL•benzinga•
Madrigal Pharmaceuticals Q4 2024 GAAP EPS $(2.71) Beats $(4.16) Estimate, Sales $103.22M Beat $98.56M Estimate. Cash And Equivalents Of $931.3M
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on February 26, 2025 by benzinga